Anti-RBD-1 (Etesevimab) antibody

General information on Anti-RBD-1 antibody

Neutralizing antibodies (NAb) have been identified as key molecules for the treatment, prevention and research of COVID-19 disease. However, due to the need to evaluate the neutralization performance of many candidates at an early stage, the development of NAb against pathogens can be a complicated process. Traditional methods of measuring virus neutralization include the use of the time-consuming virus neutralization test (VNT), pseudovirus neutralization test (pVNT), or table reduction neutralization test (PRNT), which requires also the use of facilities with strict pathogenic toxicity. (biosafety level 3). Regarding SAV-CoV-2 (the causative agent of COVID-19 disease), NAb is defined as the interaction between the virus-blocking spike protein (specifically its receptor binding domain (RBD)) and the Ability virus. Specific receptor on the surface of human cells (ACE2). Anti-CoV-RBD (G1) antibodies belong to a unique class of antibodies with neutralizing activity. Recombinant forms of RBD have been used as target antigens to be isolated from the highly diverse human COVID-19 antibody library (LiAb-SFCOVID-19 ™). Additionally, the candidate neutralizing activity is predicted by our SARS-CoV-2 Alternative Virus Neutralization Test (sVNT), which detects antibodies that can effectively compete with ACE2 for the RBD binding pouch. Furthermore, the stability and ease of production of the antibody were verified by producing milligrams in the transient system of mammalian XtenCHO.
The antibody can be used as an effective reaction reagent to study the progression of COVID-19 disease and can be used as a monitoring tool to determine the long and short-term immune development of SARS-CoV-2 in the world population.